Tiziana Life Sciences Plc - Company Profile
Powered by 
All the data and insights you need on Tiziana Life Sciences Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Tiziana Life Sciences Plc Strategy Report
- Understand Tiziana Life Sciences Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Tiziana Life Sciences Ltd (Tiziana), formerly Tiziana Life Sciences Plc, is a biotechnology company that focuses on the discovery and development of novel drugs for the treatment of cancer, autoimmune diseases and inflammatory diseases. The company's focus areas include Crohn's disease, progressive multiple sclerosis, COVID-19 and hepatocellular cancer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company’s R&D efforts focus on the development of its products for treatment of oncology, inflammation and infectious diseases. Major pipeline products include Foralumab, Milciclib and Anti IL-6R mAb. In FY2022, the company spent US$12.9 million on its R&D activities.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer